Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049060 | 0.87 | KRAS (0.49) | KRASPDE10AGSK3BCYP2D6HTR2C | |
| SCHEMBL19002462 | 0.85 | DRD3 (0.47) | GSK3BCYP2D6GAAMTNR1BBIRC2 | |
| SCHEMBL24943194 | 0.84 | GSK3B (0.48) | KRASPDE10AGSK3BCYP2D6HTR2C | |
| SCHEMBL20665207 | 0.84 | KRAS (0.47) | KRASPDE10AGSK3BCYP2D6HTR2C | |
| SCHEMBL19002565 | 0.83 | EPHX2 (0.45) | GSK3BBIRC2 | |
| SCHEMBL19002567 | 0.83 | EPHX2 (0.45) | GSK3BCYP2D6 | |
| SCHEMBL18947301 | 0.83 | MTNR1B (0.45) | MTNR1BBIRC2 | |
| SCHEMBL19002456 | 0.82 | BLM (0.47) | GSK3B | |
| SCHEMBL5667588 | 0.81 | GSK3B (0.48) | KRASPDE10AGSK3BCYP2D6DRD2 | |
| SCHEMBL5667594 | 0.81 | GSK3B (0.48) | KRASPDE10AGSK3BCYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | KRAS 608/4885PDE10A 1360/4885GSK3B 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.